DOCSLIB.ORG

Ototoxic Effects from Gentamicin Ear Drops

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ototoxic Effects from Gentamicin Ear Drops PRACTICE H EALTH AND D RUG A LERTS Ototoxic effects from gentamicin ear drops Reason for posting: Gentamicin ear age was often persistent: in 16 patients fects after the first 5–7 days of use, and drops can cause serious side effects the symptoms had not resolved at the regularly thereafter if treatment is pro- (e.g., vertigo, imbalance, ataxia, oscillat- time the case was reported to Health longed. Audiometric assessment is not ing vision, hearing loss and tinnitus) Canada.5 an appropriate screening tool for oto- when used by patients with perforated toxicity,11 because ototoxic effects of tympanic membranes or tympanostomy The drug: Several preparations of topical topical gentamicin solutions appear to tubes.1 Despite previous warnings2–4 gentamicin sulfate solution are marketed be primarily vestibular rather than ototoxic adverse events continue to oc- in Canada to treat superficial ear and eye cochlear.3,4 Although ototoxicity in pa- cur. The incidence of such events is un- infections. Indications for otic prepara- tients with intact tympanic membranes known, but 20 cases have been reported tions include otitis externa6 (“swimmer’s has not yet been reported, patients taking in Canada since 1981,5 with 17 involv- ear”). Preparations that include a steroid the drug for chronic otitis media often ing vestibular disorders and 3 involving (e.g., betamethasone) are indicated for systemically absorb detectable levels of hearing loss. In most cases the condi- acute otitis externa, eczematoid dermati- the drug.11 Thus, it may be appropriate tions being treated were middle-ear dis- tis, seborrheic dermatitis and contact to warn all patients taking gentamicin ear orders with otorrhea; in 1 case genta- dermatitis with secondary infection6 and drops of possible ototoxic effects. When micin ear drops were being given to are often prescribed for off-label use to a topical agent is required in patients treat Ménière’s disease (along with treat chronic suppurative otitis media.7 with a perforated tympanic membrane, high-dose intratympanic gentamicin in- Prolonged use of these combination top- non-ototoxic ear drops such as ciproflox- fusions). Six patients had used the drops ical agents can result in a secondary fun- acin solution may preferable. for no more than 5–7 days. The dam- gal infection and mycelial plug,7 and use of any gentamicin ear drops can lead to Eric Wooltorton the development of aminoglycoside- CMAJ Editorial Fellow resistant organisms.8 Canadian Adverse Although the risk of ototoxic effects References Reaction Newsletter from aminoglycoside otic preparations 1. Important safety information: Garasone/ 9 Garamycin [Dear Healthcare Professional Let- has long been recognized, its impor- ter]. Pointe-Claire (QC): Schering Canada Inc.; Bulletin canadien tance may have previously been under- 2002 May 30. Available: www.hc-sc.gc.ca/hpb-dgps /therapeut/htmleng/adviss_ind_e.html (accessed des effets indésirables appreciated. In a survey of 2235 oto- 2002 June 13). laryngologists in the early 1990s, 84% 2. Hélal A. Aminoglycoside ear drops and ototoxic- To receive the Newsletter and health reported using ototopical agents in the ity. Can ADR Newsl 1997;7(2):3. (Also in CMAJ product Advisories by email, join Health 1997;156[7]:1056.) Canada’s Health_Prod_Info mailing list. presence of a perforated tympanic 3. Marais J, Rutka JA. Ototoxicity and topical ear membrane, and only 3.4% reported drops. Clin Otolaryngol 1998;23(4):360-7. Go to www.hc-sc.gc.ca/hpb-dgps 4. Bath AP, Walsh RM, Bance ML, Rutka JA. Oto- /therapeut/htmleng/adr.html having witnessed irreversible ear dam- toxicity of topical gentamicin preparations. and click on "subscribe." age caused by such agents.10 Laryngoscope 1999;109:1088-93. 5. Stockwell M. Gentamicin ear drops and ototoxic- Inscrivez-vous à la liste ity: update. Can Adverse Drug Reaction Newsl 2001; What to do: Acute and uncomplicated 11(1):3-4. (Also in CMAJ 2001;164[1]:93-4.) Info_Prod_Santé de Santé Canada 6. Garamycin Ophthalmic/Otic Preparations and pour recevoir par courriel le Bulletin et otitis externa is often prevented with a Garasone Ophthalmic/Otic Preparations. In: Com- les Avis au sujet des produits de santé. few drops of vinegar in each ear after pendium of Pharmaceuticals and Specialties; Ottawa: Canadian Pharmacists Association; 2002. p. 686-7. Rendez-vous à l’adresse swimming and can be treated with an an- 7. Ontario Anti-infective Review Panel. Anti-infec- www.hc-sc.gc.ca/hpb-dgps/therapeut tiseptic solution such as aluminum ac- tive guidelines for community-acquired infections. /htmlfrn/adr.html et cliquez sur 7 2nd ed. Toronto: Publications Ontario; 2001. etate. When gentamicin ear drops are 8. Clayton MI, Osborne JE, Rutherford D, Rivron RP. « abonnement ». indicated otoscopic examination is essen- A double-blind, randomized, prospective trial of a tial, because aminoglycoside ear drops topical antiseptic versus a topical antibiotic in treat- Report adverse reactions toll free to ment of otorrhea. Clin Otolaryngol 1990;15:7-10. Health Canada • Signaler sans frais des are contraindicated in patients with a 9. Morizono T, Johnstone BM Ototoxicity of topi- effets indésirables à Santé Canada perforated tympanic membrane (includ- cally applied gentamicin using a statistical analysis of electrophysiological measurement. Acta Oto- Tel./Tél. : 866 234-2345 ing those with tympanostomy tubes). laryngol 1975;80:389-93. Fax/Téléc. : 866 678-6789 The treatment duration should be as 10. Lundy LB, Graham MD. Ototoxicity and oto- topical medications: a survey of otolaryngolo- Email/Courriel: [email protected] short as possible, often less than 7 days, gists. Am J Otol 1993;14:141-6. and the drug should be stopped immedi- 11. Lancaster JL, Mortimore S, McCormick M, Hart CA. Systemic absorption of gentamicin in the ately if ototoxic symptoms develop. Pa- management of active mucosal chronic otitis me- tients should be assessed for adverse ef- dia. Clin Otolaryngol 1999;24(5):435-9. 56 JAMC • 9 JUILL. 2002; 167 (1) © 2002 Canadian Medical Association or its licensors.
Load more

Recommended publications
  • Instruction Sheet: Otitis Externa
    University of North Carolina Wilmington Abrons Student Health Center INSTRUCTION SHEET: OTITIS EXTERNA The Student Health Provider has diagnosed otitis externa, also known as external ear infection, or swimmer's ear. Otitis externa is a bacterial/fungal infection in the ear canal (the ear canal goes from the outside opening of the ear to the eardrum). Water in the ear, from swimming or bathing, makes the ear canal prone to infection. Hot and humid weather also predisposes to infection. Symptoms of otitis externa include: ear pain, fullness or itching in the ear, ear drainage, and temporary loss of hearing. These symptoms are similar to those caused by otitis media (middle ear infection). To differentiate between external ear infection and middle ear infection, the provider looks in the ear with an instrument called an otoscope. It is important to distinguish between the two infections, as they are treated differently: External otitis is treated with drops in the ear canal, while middle ear infection is sometimes treated with an antibiotic by mouth. MEASURES YOU SHOULD TAKE TO HELP TREAT EXTERNAL EAR INFECTION: 1. Use the ear drops regularly, as directed on the prescription. 2. The key to treatment is getting the drops down into the canal and keeping the medicine there. To accomplish this: Lie on your side, with the unaffected ear down. Put three to four drops in the infected ear canal, then gently pull the outer ear back and forth several times, working the medicine deeper into the ear canal. Remain still, good-ear-side-down for about 15 minutes.
    [Show full text]
  • Objective Measures of Ototoxicity
    The following article appeared in the September 2005 issue (Vol. 9, No. 1, pp. 10-16) of the Division 6 publication Perspectives on Hearing and Hearing Disorders: Research and Diagnostics. To learn more about Division 6, contact the ASHA Action Center at 1-800-498-2071 or visit the division’s Web page at www.asha.org/about/membership-certification/divs/div_6.htm. Objective Measures of Ototoxicity Elizabeth Leigh-Paffenroth Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR Department of Otolaryngology, Oregon Health & Science University Portland, OR Kelly M. Reavis, Jane S. Gordon, Kathleen T. Dunckley Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR Stephen A. Fausti and Dawn Konrad-Martin Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical Center Portland, OR Department of Otolaryngology, Oregon Health & Science University, Portland, OR A leading cause of preventable sensorineural hear- of patients who are unable to provide reliable re- ing loss is therapeutic treatment with medications that sponses; subsequently, many of these patients do not are toxic to inner ear tissues, including certain drugs receive monitoring for ototoxic-induced changes in used to fight cancer and life-threatening infectious dis- their hearing. The development of objective measures eases. Ototoxic-induced hearing loss typically begins that do not require patient cooperation is necessary to in the high frequencies and progresses to lower fre- monitor all patients receiving ototoxic drugs. quencies as drug administration continues (Campbell Two objective measures offer promise in their abil- & Durrant, 1993; Campbell et al., 2003; Macdonald, ity to detect and to monitor hearing changes caused by Harrison, Wake, Bliss, & Macdonald, 1994).
    [Show full text]
  • ICD-9 Diseases of the Ear and Mastoid Process 380-389
    DISEASES OF THE EAR AND MASTOID PROCESS (380-389) 380 Disorders of external ear 380.0 Perichondritis of pinna Perichondritis of auricle 380.00 Perichondritis of pinna, unspecified 380.01 Acute perichondritis of pinna 380.02 Chronic perichondritis of pinna 380.1 Infective otitis externa 380.10 Infective otitis externa, unspecified Otitis externa (acute): NOS circumscribed diffuse hemorrhagica infective NOS 380.11 Acute infection of pinna Excludes: furuncular otitis externa (680.0) 380.12 Acute swimmers' ear Beach ear Tank ear 380.13 Other acute infections of external ear Code first underlying disease, as: erysipelas (035) impetigo (684) seborrheic dermatitis (690.10-690.18) Excludes: herpes simplex (054.73) herpes zoster (053.71) 380.14 Malignant otitis externa 380.15 Chronic mycotic otitis externa Code first underlying disease, as: aspergillosis (117.3) otomycosis NOS (111.9) Excludes: candidal otitis externa (112.82) 380.16 Other chronic infective otitis externa Chronic infective otitis externa NOS 380.2 Other otitis externa 380.21 Cholesteatoma of external ear Keratosis obturans of external ear (canal) Excludes: cholesteatoma NOS (385.30-385.35) postmastoidectomy (383.32) 380.22 Other acute otitis externa Excerpted from “Dtab04.RTF” downloaded from website regarding ICD-9-CM 1 of 11 Acute otitis externa: actinic chemical contact eczematoid reactive 380.23 Other chronic otitis externa Chronic otitis externa NOS 380.3 Noninfectious disorders of pinna 380.30 Disorder of pinna, unspecified 380.31 Hematoma of auricle or pinna 380.32 Acquired
    [Show full text]
  • Preventing Hearing Loss Caused by Chemical (Ototoxicity) and Noise Exposure
    Preventing Hearing Loss Caused by Chemical (Ototoxicity) and Noise Exposure Safety and Health Information Bulletin SHIB 03-08-2018 DHHS (NIOSH) Publication No. 2018-124 Introduction Millions of workers are exposed to noise in the workplace every day and when uncontrolled, noise exposure may cause permanent hearing loss. Research demonstrates exposure to certain chemicals, called ototoxicants, may cause hearing loss or balance problems, regardless of noise exposure. Substances including certain pesticides, solvents, and pharmaceuticals that contain ototoxicants can negatively affect how the ear functions, causing hearing loss, and/or affect balance. Source/Copyright: OSHA The risk of hearing loss is increased when workers are exposed to these chemicals while working around elevated noise levels. This combination often results in hearing loss that can be temporary or permanent, depending on the level of noise, the dose of the chemical, and the duration of the exposure. This hearing impairment affects many occupations and industries, from machinists to firefighters. Effects on Hearing Harmful exposure to ototoxicants may occur through inhalation, ingestion, or skin absorption. Health effects caused by ototoxic chemicals vary based on exposure frequency, intensity, duration, workplace exposure to other hazards, and individual factors such as age. Effects may be temporary or permanent, can affect hearing sensitivity and result in a standard threshold shift. Since chemicals can affect central portions of the auditory system (e.g., nerves or nuclei in the central nervous system, the pathways to the brain or in the brain itself), not only do sounds need to be louder to be detected, but also they lose clarity. Specifically, speech discrimination dysfunction, the ability to hear voices separately from background noise, may occur and involve: .
    [Show full text]
  • Differential Diagnosis and Treatment of Hearing Loss JON E
    Differential Diagnosis and Treatment of Hearing Loss JON E. ISAACSON, M.D., and NEIL M. VORA, M.D., Milton S. Hershey Medical Center, Hershey, Pennsylvania Hearing loss is a common problem that can occur at any age and makes verbal communication difficult. The ear is divided anatomically into three sections (external, middle, and inner), and pathology contributing to hearing loss may strike one or more sections. Hearing loss can be cat- egorized as conductive, sensorineural, or both. Leading causes of conductive hearing loss include cerumen impaction, otitis media, and otosclerosis. Leading causes of sensorineural hear- ing loss include inherited disorders, noise exposure, and presbycusis. An understanding of the indications for medical management, surgical treatment, and amplification can help the family physician provide more effective care for these patients. (Am Fam Physician 2003;68:1125-32. Copyright© 2003 American Academy of Family Physicians) ore than 28 million Amer- tive, the sound will be heard best in the icans have some degree of affected ear. If the loss is sensorineural, the hearing impairment. The sound will be heard best in the normal ear. differential diagnosis of The sound remains midline in patients with hearing loss can be sim- normal hearing. Mplified by considering the three major cate- The Rinne test compares air conduction gories of loss. Conductive hearing loss occurs with bone conduction. The tuning fork is when sound conduction is impeded through struck softly and placed on the mastoid bone the external ear, the middle ear, or both. Sen- (bone conduction). When the patient no sorineural hearing loss occurs when there is a longer can hear the sound, the tuning fork is problem within the cochlea or the neural placed adjacent to the ear canal (air conduc- pathway to the auditory cortex.
    [Show full text]
  • Why Is Drug-Induced Ototoxicity Still Not Preventable Nor Is It Treatable in 2019? - a Literature Review of Aminoglycoside and Cisplatin Ototoxicity Cherrabi Kaoutar*
    Review Article iMedPub Journals Archives of Medicine 2020 www.imedpub.com Vol.12 No.2:3 ISSN 1989-5216 DOI: 10.36648/1989-5216.12.2.304 Why is Drug-Induced Ototoxicity Still Not Preventable nor is it Treatable in 2019? - A Literature Review of Aminoglycoside and Cisplatin Ototoxicity Cherrabi Kaoutar* Department of Oto-Rhino-Laryngology and Cervico-Facial Studies, Fez, Morocco *Corresponding author: Cherrabi Kaoutar, Resident, Department of Oto-Rhino-Laryngology and Cervico-Facial Studies, Fez, Morocco, Tel: 0679382957; E-mail: [email protected] Received date: October 17, 2019; Accepted date: March 02, 2019; Published date: March 09, 2020 Citation: Cherrabi K (2020) Why is Drug-Induced Ototoxicity Still Not Preventable nor is it Treatable in 2019? - A Literature Review of Aminoglycoside and Cisplatin Ototoxicity. Arch Med Vol: 12 Iss: 2:3 Copyright: ©2020 Cherrabi K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The thorough exploration of inner ear proteome, transcriptome, and genome in physiological and Abstract pathological contexts as potential biomarkers of early stages of cell lesions: The clinical application would not Oto-toxicity is defined by cochlear and or vestibular only allow a more specific understanding of different cellular lesions due to the use of drugs. The difference in mechanisms of iatrogenic oto-toxicity, but also allow new specific mechanisms, the great semi logical variability, the insights into targeted protective and post-lesional heterogeneity of incriminated drugs, the inaccessibility to therapies.
    [Show full text]
  • Gentamicin Ototoxicity: a 23-Year Selected Case Series of 103 Patients
    Research Gentamicin ototoxicity: a 23-year selected case series of 103 patients Rebekah M Ahmed entamicin is an important bac- MB BS, FRACP, Abstract Neurology Fellow1 tericidal antibiotic with two Objective: To review patients with severe bilateral vestibular loss associated serious potential adverse Imelda P Hannigan G with gentamicin treatment in hospital. RN, Neuro-otology Nurse1 effects: nephrotoxicity and ototoxicity. Design and setting: A retrospective case series of presentations to a balance Clinicians are well aware that rising Hamish G MacDougall disorders clinic between 1988 and 2010. PhD, serum creatinine levels in patients Vestibular Scientist2 treated with gentamicin could indicate Main outcome measures: Relationship between vestibulotoxicity and gentamicin dose or dosing profile; indications for prescribing gentamicin. Raymond C Chan nephrotoxicity. However, many do MB BS, FRACP, FRCPA, not know that, contrary to textbooks Results: 103 patients (age, 18–84 years; mean, 64 years) presented with Infectious Diseases imbalance, oscillopsia or both, but none had vertigo. Only three noted some Physician1 and antibiotic guidelines, gentamicin hearing impairment after having gentamicin, but audiometric thresholds for all ototoxicity causes impairment of G Michael Halmagyi 1,2 patients were consistent with their age. In all patients, the following tests gave MD, FRACP, vestibular, not auditory, function. positive results: a bilateral clinical head-impulse test, a vertical head-shaking Neurologist1 Vestibulotoxicity is frequently over- test for vertical oscillopsia, and a foam Romberg test. In 21 patients, imbalance 3-7 looked in patients having gentamicin, occurred during gentamicin treatment (ignored or dismissed by prescribers in 1 Department of Neurology, so that severe, irreversible, bilateral 20) and in 66 after treatment; the remaining 16 could not recall when symptoms Royal Prince Alfred Hospital, Sydney, NSW.
    [Show full text]
  • The Discharging Ear: a Practical Approach
    THE DISCHARGING EAR THE DISCHARGING EAR: A PRACTICAL APPROACH Otorrhoea is a common presenting symptom, the cause of which can usually be established on the basis of the history and clinical examination. The substances that the ear may discharge include wax, pus, mucus, blood, cere- brospinal fluid (CSF) and saliva. Wax is the normal secretion of the glands of the external ear canal, and patients complaining of wax discharging from the ear should be reassured that it is not abnormal. The common pathological causes of otorrhoea are the following: • chronic suppurative otitis media (CSOM) with/without cholesteatoma • otitis externa • acute otitis media with perforation of the tympanic membrane • CSF otorrhoea • external or middle ear neoplasms R Y SEEDAT • granulomatous diseases — tuberculosis, atypical mycobacteria, Wegener’s granulomatosis. MB ChB, MMed (ORL), FCORL (SA) Specialist/Lecturer CLINICAL ASSESSMENT Department of Otorhinolaryngology History Universitas Hospital and The evaluation of a patient with otorrhoea starts with his/her history. The patient University of the Free State should be asked about the nature and duration of the discharge, and about the Bloemfontein following otological symptoms: • otorrhoea Riaz Seedat obtained the MB ChB degree • hearing loss • tinnitus from the University of Natal and spe- • otalgia cialised in ENT surgery at the University of • vertigo the Free State, Bloemfontein. He has been •facial palsy. a consultant in the Department of Otorhinolaryngology at Universitas The colour of the fluid can suggest the cause of the otorrhoea. A purulent dis- Hospital and the University of the Free charge indicates the presence of infection, while a bloody discharge may follow trauma or occur with granulation tissue associated with chronic infection.
    [Show full text]
  • 3.2.1 Safety of Antibiotic Ear Drops in Children with Grommets
    Safety of antibiotic ear drops in children with grommets CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 8 June 2017 Agenda item 3.2.1 Title Safety of Antibiotic Ear Drops in children with Grommets Medsafe Pharmacovigilance Submitted by Paper type For advice Team Active constituent(s) Medicines Sponsors Clioquinol; Locorten-Vioform AFT Pharmaceuticals Flumetasone pivalate Locacorten-Viaform Ciprofloxacin; Pharmaco (NZ) Ltd Ciproxin HC Otic Ear drops Hydrocortisone Framycetin; Sanofi-aventis New Zealand limited Gramicidin; Sofradex Dexamethasone Framycetin Soframycin Sanofi-aventis New Zealand limited Neomycin; Pharmacy Retailing (NZ) Ltd t/a Gramicidin; Kenacomb Ear drops Healthcare Logistics Nystatin; Triamcinolone Funding Locorten-Vioform/Locacorten-Viaform; Kenacomb; Sofradex*; Soframycin*. *Part funded only Previous MARC None meetings International action None Prescriber Update None Schedule Prescription Advice sought The Committee is asked to advise whether: − there is evidence of a difference in the risk of ototoxicity between the antibiotic containing ear drops when used in children with grommets or in patients with a perforated tympanic membrane − the sponsor for Ciproxin HC (quinolone) ear drops should be given the opportunity to remove the contraindication for use in patients with a perforated tympanic membrane and replace it with a warning statement − the sponsor for Locorten-Vioform/Locacorten-Viaform (hydroxyquinolone) include information on the risk of ototoxicity − the sponsors for Sofradex, Soframycin and
    [Show full text]
  • Tympanosclerosis Definition
    Tympanosclerosis Definition • Tympanosclerosis (TS): calcification and hardening of tissue in the eardrum and middle ear • Unclear etiology but cause may include: • Long-term otitis media • Atherosclerosis • Insertion of tympanostomy tube Epidemiology • 5% among pediatric otolaryngology clinic visits • In 23%-40% of children who had glue ear (a fluid filled middle ear) or prior tympanostomy tubes. • Recent increase in incidence could be due to increased awareness and detection Classification • Myringosclerosis calcification only within the tympanic membrane usually less extensive than tympanosclerosis • Intratympanic tympanosclerosis when occurring at other location within the middle ear including the ossicular chain, middle ear mucosa or the mastoid cavity Signs and Symptoms • Myringosclerosis: Generally asymptomatic without hearing loss • Tympanosclerosis: Can result in significant hearing loss. However, hearing loss can often be completely reversed or improve with treatment Common History Findings • Patients with prior myringotomy and tube placement are at increased risk of TS or MS • Prolonged otitis media also increases risk for TS Tympanosclerosis (video) Tympanosclerosis appears as a chalky white material within the eardrum substance. Dense sclerosis, causes eardrum thickening and may involve the ossicles with impairment of hearing. (play video to see otoscopy findings) Tympanosclerosis Note the characteristic chalky white calcification of the tympanic membranes shown above. http://me.hawkelibrary.com/new/main.php?g2_itemId=1744
    [Show full text]
  • Case Series on External Auditory Canal Cholesteatoma: an Entity Often Misdiagnosed
    International Journal of Otorhinolaryngology and Head and Neck Surgery Hajare PS et al. Int J Otorhinolaryngol Head Neck Surg. 2020 Jun;6(6):1179-1182 http://www.ijorl.com pISSN 2454-5929 | eISSN 2454-5937 DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20202222 Case Series Case series on external auditory canal cholesteatoma: an entity often misdiagnosed Priti S. Hajare, O. Padmavathy* Department of Otorhinolaryngology, Head and Neck Surgery, Jawaharlal Nehru Medical College, Belgaum, Karnataka, India Received: 29 March 2020 Revised: 29 April 2020 Accepted: 30 April 2020 *Correspondence: Dr. O. Padmavathy, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT External auditory canal (EAC) cholesteatoma is a rare disease. EAC cholesteatoma presents with chronic dull aching pain with normal hearing. It is diagnosed by clinical examination and radiological investigation. Due to its rarity it is important to differentiate it from other external ear conditions. We prospectively analysed four cases of cholesteatoma of the external auditory canal in a period of 18 months. All of our patients underwent surgery. In three cases, the cholesteatoma was restricted to the external auditory canal, while in one case it was extending into the antrum.
    [Show full text]
  • Drug-Induced Ototoxicity
    Continuing Education Drug-Induced Ototoxicity Authors: Erin Bilgili Pharm.D. Harrison School of Pharmacy, Auburn University Jarrid Casimir Pharm.D. Harrison School of Pharmacy, Auburn University Kelli Pickard Pharm.D. Harrison School of Pharmacy, Auburn University Corresponding Author: Wesley Lindsey, Pharm.D. Associate Clinical Professor of Pharmacy Practice Drug Information and Learning Resource Center Harrison School of Pharmacy, Auburn University Universal Activity #: 0178-0000-17-101-H01-P | 1.25 contact hours (.125 CEUs) Initial Release Date: August 7, 2017 | Expires: May 7, 2020 Learning Objectives: After this article, the reader should be able to... • Define ototoxicity and describe the risk factors • Identify the most common classes of ototoxic medications • Discuss the different mechanisms of ototoxicity • Develop a patient-specific monitoring plan • Refer a patient to additional resources if needed Alabama Pharmacy Association | 334.271.4222 | www.aparx.org | [email protected] 1 What is ototoxicity? middle ear, and inner ear. Figure 1 illustrates the Ototoxicity is defined by Hawkins as “the tendency anatomy of the ear and its associated structures. of certain therapeutic agents and other chemical ● Outer ear: external portion of the ear, substances to cause functional impairment and consisting of the pinna, or auricle, and the ear cellular degeneration of the tissues of the inner ear, canal. and especially of the end organs and neurons of the ● Middle ear: includes the eardrum and three cochlear and vestibular divisions of the eighth cranial tiny bones of the middle ear, ending at the nerve”.1 This functional impairment and cellular round window that leads to the inner ear. degeneration can lead to ringing in the ear (tinnitus), ● Inner ear: contains both the organ of hearing hearing loss, or balance disorders.2 Any drug with (cochlea) and the organ of balance the potential to cause toxic effects to the structures of (vestibulum).
    [Show full text]